Wed, Apr 23, 2014, 4:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Nanosphere, Inc. (NSPH) Message Board

n_s_sherlock 129 posts  |  Last Activity: Dec 18, 2013 9:55 PM Member since: Feb 3, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    When We Invested Here Mid 2013

    by norsemanwam Dec 18, 2013 8:33 PM
    n_s_sherlock n_s_sherlock Dec 18, 2013 9:55 PM Flag

    Thou doth protest too much

    And that is a sure sign that know nothing, do nothing, and are a BS artist.

  • Reply to

    When We Invested Here Mid 2013

    by norsemanwam Dec 18, 2013 8:33 PM
    n_s_sherlock n_s_sherlock Dec 18, 2013 8:37 PM Flag

    You keep saying "we". Are you referring to your other personalities/alter egos or the voices in your head that talk to you?

  • n_s_sherlock n_s_sherlock Nov 20, 2013 9:26 AM Flag

    here is what the editorial about the studies published yesterday in the NEJM said about the test...

    "Second, it would appear that, despite the variation in trial design, these trials indicate that this pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or, at best, marginal usefulness, given the cost and effort required to perform this testing."

  • From today's NEJM...

    Embargoed for Release: Tuesday, November 19, 2013, 11:45 a.m. EST

    Genetic data does not improve anticoagulation control with warfarin

    NIH-funded study shows genotyping adds no benefit when added to a clinically-guided dosing formula

    Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in achieving stable anticoagulation than using only clinical information, according to a National Institutes of Health-funded clinical trial. In addition, the study found that in African-Americans, anticoagulation control was lower in the genetics-based approach compared to the clinically-based method.

    The results of the Clarification of Optimal Anticoagulation through Genetics (COAG) trial, supported by the NIH's National Heart, Lung, and Blood Institute, were presented today at the American Heart Association (AHA) Scientific Sessions in Dallas. The study was published simultaneously in the New England Journal of Medicine.

  • n_s_sherlock n_s_sherlock Nov 19, 2013 7:18 PM Flag

    Looks like it is you getting the schooling....

  • $2.4M revenues misses average Wall Street estimates of $2.6M.
    Losses were 0.16 per share when analysts, on average, had estimated a 0.15 loss per share

    Sentiment: Strong Sell

  • n_s_sherlock n_s_sherlock Oct 3, 2013 11:51 AM Flag

    A 510(k) submission requires user fees, so it looks like the FDA HAS NOT even accepted SQNM's submission for review.

    Sentiment: Sell

  • wow doing terrible still down 20% since Jun 10

  • n_s_sherlock by n_s_sherlock Sep 12, 2013 4:15 PM Flag

    Man the lifeboats

    Sentiment: Strong Sell

  • Reply to

    BioFire has been bought out, is NSPH next?

    by socceref_1999 Sep 3, 2013 1:19 PM
    n_s_sherlock n_s_sherlock Sep 3, 2013 1:42 PM Flag

    BioFire was acquired for their IP, not for their products. BioMerieux now gets their revolutionary Ip for performing ultra-fast PCR, 50 cycles of PCR in one minute. They presented it at the Clinical Virology Symposium back in April.

    NSPH has nothing even close.

    Sentiment: Sell

  • "July 18, 2013 | PCR Insider

    BioFire Diagnostics has been awarded $1.4 million from the National Institutes of Health for the first year of a planned three-year project to clinically validate the company's FilmArray gastrointestinal panel and help shepherd it through the US Food and Drug Administration approval process.

    BioFire is currently setting up clinical testing sites for the assay with the hope of submitting the test to the US Food and Drug Administration by early 2014 in order to achieve regulatory clearance and commence sales later in the year…."

    Sentiment: Strong Sell

  • n_s_sherlock by n_s_sherlock Jun 26, 2013 10:31 AM Flag

    "FDA Clears BioFire's Sepsis Panel
    June 25, 2013

    By a GenomeWeb staff reporter

    NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared BioFire Diagnostics' FilmArray Blood Culture Identification, or BCID, Panel, the company announced today.

    The FDA clearance follows CE marking of the 27-target panel earlier this month. The Salt Lake City company filed its 510(k) submission to FDA for the test in April.

    According to BioFire, the panel provides results from positive blood cultures and can identify more than 100 blood pathogens known to cause sepsis. It is designed to help hospitals identify organisms that cause blood stream infections more rapidly than can be achieved with other current methods.

    It can identify a pathogen in nine out of 10 positive blood cultures in about one hour and is the only test that can provide results for gram-positive bacteria, gram-negative bacteria, and yeast that cause bloodstream infections, BioFire said.

    It added that BCID includes the first FDA-cleared diagnostic test for the blaKPC gene, which is associated with carbapenem resistance in Klebsiella pneumoniae, Acinetobacter spp, and carbapenem-resistant Enterobacteriaceae. It also tests for common antimicrobial resistance genes associated with methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci.

    "We expect an immediate increase in revenues since existing FilmArray customers have indicated that they intend to adopt the BCID Panel," BioFire CEO Kirk Ririe said in a statement."

    More agents and the only test with carbapenem resistance testing too.

    Sentiment: Sell

  • n_s_sherlock n_s_sherlock Jun 21, 2013 10:53 AM Flag

    Now that there is an FDA approved HCV genotyping test, I wonder if the FDA will take enforcement action against GNMK for selling their Research Use Only assay to clinical labs for diagnostic use?

    Sentiment: Sell

  • "FDA approves first genotyping test for patients with hepatitis C virus

    The U.S. Food and Drug Administration today approved a test that identifies the genotypeof hepatitis C virus (HCV) that apatientis carrying. The Abbott RealTime HCV Genotype II, which can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5,using a sample of an infected patient’s blood plasma or serum, will aid health care professionals in determining the appropriate approach to treatment. Because the various HCV genotypes respond differently to available drug therapies, knowing the type of HCV a person is infected with can result in better patient outcomes.

    “Tests such as this one can help physicians gain an understanding of a patient’s HCV status,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in FDA’s Center for Devices and Radiological Health. “Along with other clinical factors, the particular type of HCV is an important consideration in aiding health care professionals in determining if and when to initiate treatment and the appropriate type of treatment.”

    The Abbott RealTime HCV Genotype II is approved for individuals known to be chronically infected with HCV. It is not approved for use as a diagnostic test or as a screening test for the presence of HCV genetic material in blood, blood products or tissue donors. It has not been evaluated in newborns or pediatric patients, or in patients with compromised immune systems, such as people with AIDS.

    The FDA based its approval of the Abbott RealTime HCV Genotype II, in part, on the assessment of the test's accuracy in differentiating specific HCV viral genotypes compared to a validated genesequencing method. The FDA also reviewed data from investigators demonstrating the relationship between HCV genotype and effectiveness of drug therapy."

    ABT beat them thru the FDA and ABT also has an approved HCV viral load test.

    Sentiment: Strong Sell

  • n_s_sherlock n_s_sherlock Jun 17, 2013 8:19 PM Flag

    Ummmm....no.

    If they already had $11M for Q1 as you claimed, it means total revenues for the remaining three quarters combined will be less than $19M.

    After all, they claimed in today's PR that the annual revenue was being lowered to $30....for the entire year.

    Sentiment: Strong Sell

  • n_s_sherlock n_s_sherlock Jun 16, 2013 8:02 PM Flag

    I never said they licensed any test, only gene patents for DNA sequences and use of those sequences.

    Apparently it is YOU and the other pampers here that keep coming up with intentionally misleading #$%$.

    Sentiment: Strong Sell

  • n_s_sherlock n_s_sherlock Jun 16, 2013 11:48 AM Flag

    No, but they certain have licensed a few for all of their test, include those for antibiotic resistance. By getting exclusive license they had hoped to exclude others from the market.

    That's not going to happen now.

    Sentiment: Sell

  • n_s_sherlock n_s_sherlock Jun 14, 2013 3:54 PM Flag

    The SCOTUS opinion wasn't until YESTERDAY, which was Thursday, June 13.

    Apparently you can't seem to get anything correct.

    Sentiment: Sell

  • n_s_sherlock n_s_sherlock Jun 13, 2013 9:54 AM Flag

    Yeah, I heard that too. Apparently the Senior Director didn't even stay for a year before leaving.

    Sentiment: Sell

  • Reply to

    It's just profit taking.

    by dicksteen Jun 12, 2013 8:27 PM
    n_s_sherlock n_s_sherlock Jun 12, 2013 9:35 PM Flag

    No, it is just as I told you yesterday. It is because og sympathetic pains as a result of LMNX taking 60% of GNMK's business away yesterday because their technology is more robust and has higher throughput that the competition.

    The institutions realize the same thing is/will happen with NSPH.

    Sentiment: Sell

NSPH
1.85-0.09(-4.64%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.